Transmedics Group Inc [TMDX] stock is trading at $117.07, up 3.24%. An important factor to consider is whether the stock is rising or falling in short-term value. The TMDX shares have lost -4.15% over the last week, with a monthly amount drifted -2.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on October 23, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $148 for it. Previously, Jefferies started tracking the stock with Buy rating on October 13, 2025, and set its price target to $145. On September 16, 2025, Evercore ISI initiated with an Outperform rating and assigned a price target of $155 on the stock. Stifel started tracking the stock assigning a Hold rating and suggested a price target of $115 on September 04, 2025. JP Morgan downgraded its rating to a Neutral and reduced its price target to $75 on December 17, 2024. Needham downgraded its rating to Hold for this stock on November 22, 2024. In a note dated October 29, 2024, Oppenheimer reiterated an Outperform rating on this stock and revised its target price from $200 to $125.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $145.50 over the past year. Currently, Wall Street analysts expect the stock to reach $147 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $117.07 at the most recent close of the market. An investor can expect a potential return of 25.57% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 566.35M for the trailing twelve months, which represents a growth of 32.24%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.31 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 112.72 points at the first support level, and at 108.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 120.20, and for the 2nd resistance point, it is at 123.33.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 7.69. On the other hand, the Quick Ratio is 7.13, and the Cash Ratio is 5.85. Considering the valuation of this stock, the price to sales ratio is 7.06, the price to book ratio is 11.25 and price to earnings (TTM) ratio is 47.29.
Transactions by insiders
Recent insider trading involved Hassanein Waleed H, President & CEO, that happened on Nov 17 ’25 when 8775.0 shares were purchased. Director, Basile Edward M completed a deal on Oct 29 ’25 to sell 4142.0 shares. Meanwhile, Director EDWARD BASILE bought 4142.0 shares on Oct 29 ’25.
